Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status
Phipatanakul W, Papadopoulos NG, Hernandez-Trujillo V, Hamelmann E, Zeiger RS, Ducharme FM, Jain N, Xia C, Gall R, Pandit-Abid N, Siddiqui S, et al. (2022)
Allergologie 45(8): 604.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Phipatanakul, W.;
Papadopoulos, N. G.;
Hernandez-Trujillo, V.;
Hamelmann, EckardUniBi;
Zeiger, R. S.;
Ducharme, F. M.;
Jain, N.;
Xia, C.;
Gall, R.;
Pandit-Abid, N.;
Siddiqui, S.;
Jacob-Nara, J. A.
Alle
Alle
Erscheinungsjahr
2022
Serien- oder Zeitschriftentitel
Allergologie
Band
45
Ausgabe
8
Seite(n)
604
Konferenz
17. Deutscher Allergiekongress
Konferenzort
Wiesbaden
Konferenzdatum
2022-09-08 – 2022-09-10
ISSN
0344-5062
Page URI
https://pub.uni-bielefeld.de/record/2969873
Zitieren
Phipatanakul W, Papadopoulos NG, Hernandez-Trujillo V, et al. Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status. Allergologie. 2022;45(8):604.
Phipatanakul, W., Papadopoulos, N. G., Hernandez-Trujillo, V., Hamelmann, E., Zeiger, R. S., Ducharme, F. M., Jain, N., et al. (2022). Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status. Allergologie, 45(8), 604.
Phipatanakul, W., Papadopoulos, N. G., Hernandez-Trujillo, V., Hamelmann, Eckard, Zeiger, R. S., Ducharme, F. M., Jain, N., et al. 2022. “Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status”, Allergologie, 45 (8): 604.
Phipatanakul, W., Papadopoulos, N. G., Hernandez-Trujillo, V., Hamelmann, E., Zeiger, R. S., Ducharme, F. M., Jain, N., Xia, C., Gall, R., Pandit-Abid, N., et al. (2022). Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status. Allergologie 45, 604.
Phipatanakul, W., et al., 2022. Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status. Allergologie, 45(8), p 604.
W. Phipatanakul, et al., “Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status”, Allergologie, vol. 45, 2022, pp. 604.
Phipatanakul, W., Papadopoulos, N.G., Hernandez-Trujillo, V., Hamelmann, E., Zeiger, R.S., Ducharme, F.M., Jain, N., Xia, C., Gall, R., Pandit-Abid, N., Siddiqui, S., Jacob-Nara, J.A., Rowe, P.J., Deniz, Y.: Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status. Allergologie. 45, 604 (2022).
Phipatanakul, W., Papadopoulos, N. G., Hernandez-Trujillo, V., Hamelmann, Eckard, Zeiger, R. S., Ducharme, F. M., Jain, N., Xia, C., Gall, R., Pandit-Abid, N., Siddiqui, S., Jacob-Nara, J. A., Rowe, P. J., and Deniz, Y. “Dupilumab efficacy in VOYAGE pediatric patients with uncontrolled, moderate-to-severe type 2 inflammatory asthma by allergen sensitization status”. Allergologie 45.8 (2022): 604.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar